---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-139180"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:22:10.928863+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022

## Summary
- Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.
- Nine-month 2021 net loss of $2.1M ($0.22 per share) vs $3.8M ($0.45 per share) in prior comparable period.
- Cash on-hand $2.0M as of Sep 30, 2021, up $1.5M from prior year.
- Proceeds of $2.6M from private placements of 1.3M shares and warrants in first nine months of 2021.
- Expects current cash to fund operating expenses and capex into Q2 2022.

## SEC filing metadata
- accession: 0001104659-21-139180
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000110465921139180/0001104659-21-139180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000110465921139180/tm2132943d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-139180
- JSON: https://secwatch.observer/filing/0001104659-21-139180.json
- Plain text: https://secwatch.observer/filing/0001104659-21-139180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.